Literature DB >> 28765905

miR-663 promotes NPC cell proliferation by directly targeting CDKN2A.

Shaoqiang Liang1, Ning Zhang1, Yanming Deng1, Lusi Chen1, Yang Zhang1, Zhenhe Zheng1, Weijun Luo1, Zhiqian Lv1, Shaoen Li1, Tao Xu1.   

Abstract

MicroRNAs (miRs) act as important regulators during the development and progression of human cancer; however, the regulatory mechanism of miR-663 in nasopharyngeal carcinoma (NPC) remains unclear. The present study demonstrated that serum miR‑663 levels were significantly increased in patients with NPC compared with healthy controls. In addition, the serum levels of miR‑663 were associated with the grade, lymph node metastasis and clinical stage of NPC. The expression of miR‑663 was increased in NPC C666‑1 cells, compared with normal nasopharyngeal epithelial NP69 cells. The knockdown of miR‑663 markedly decreased the proliferation of C666‑1 cells through the induction of cell cycle arrest at the G1 stage. Cyclin‑dependent kinase inhibitor 2A (CDKN2A) was hypothesized to be a putative target of miR‑663. Further investigation confirmed that miR‑663 was able to directly bind to the 3' untranslated region of CDKN2A mRNA, and to negatively regulate CDKN2A protein expression in C666‑1 cells. Inhibition of CDKN2A expression attenuated the suppressive effects of miR‑663 knockdown on the proliferation and cell cycle progression of C666‑1 cells. In addition, it was observed that the mRNA and protein levels of CDKN2A were decreased in C666‑1 cells compared with NP69 cells. In conclusion, the results of the present study demonstrated that miR‑663 promoted the proliferation and cell cycle progression of NPC cells by directly targeting CDKN2A, suggesting that miR‑663 may become a potential therapeutic target for the treatment of NPC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28765905     DOI: 10.3892/mmr.2017.7129

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

1.  Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.

Authors:  Shengshu Li; Xiaoxin Lu; Dongyang Zheng; Weizong Chen; Yuzhu Li; Fang Li
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-30       Impact factor: 4.322

Review 2.  Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential.

Authors:  Dharambir Kashyap; Hardeep Singh Tuli; Vivek Kumar Garg; Neelam Goel; Anupam Bishayee
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

Review 3.  MiR-663, a MicroRNA Linked with Inflammation and Cancer That Is under the Influence of Resveratrol.

Authors:  Jean-Jacques Michaille; Victoria Piurowski; Brooke Rigot; Hesham Kelani; Emily C Fortman; Esmerina Tili
Journal:  Medicines (Basel)       Date:  2018-07-09

4.  miR-429 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by downregulation of TLN1.

Authors:  Zhihui Wang; Zhiquan Zhu; Zhong Lin; Youli Luo; Zibin Liang; Caibin Zhang; Jianxu Chen; Peijian Peng
Journal:  Cancer Cell Int       Date:  2019-04-30       Impact factor: 5.722

Review 5.  MiRNAs in Radiotherapy Resistance of Nasopharyngeal Carcinoma.

Authors:  Yutong Tian; Lu Tang; Pin Yi; Qing Pan; Yaqian Han; Yingrui Shi; Shan Rao; Shiming Tan; Longzheng Xia; Jinguan Lin; Linda Oyang; Yanyan Tang; Jiaxin Liang; Xia Luo; Qianjin Liao; Hui Wang; Yujuan Zhou
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

6.  Glycyrrhetinic Acid-Induced MiR-663a Alleviates Hepatic Stellate Cell Activation by Attenuating the TGF-β/Smad Signaling Pathway.

Authors:  Xin-Xin Guo; Wen-Na Yang; Ben-Sheng Dong; Jia-Wei Shang; Shi-Bing Su; Xiu-Li Yan; Hui Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-11       Impact factor: 2.629

7.  miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma.

Authors:  Chengshuo Zhang; Baomin Chen; Ao Jiao; Feng Li; Ning Sun; Guoqing Zhang; Jialin Zhang
Journal:  BMC Cancer       Date:  2018-11-28       Impact factor: 4.430

8.  MicroRNA-663 Regulates Melanoma Progression by Inhibiting FHL3.

Authors:  Saijun Liu; Yunfeng Hu; Shi Wu; Yong He; Liehua Deng
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  miR‑140‑5p inhibits the proliferation of multiple myeloma cells by targeting VEGFA.

Authors:  Min Liu; Huimin Liu; Jing Zhou; Zhuojun Yu
Journal:  Mol Med Rep       Date:  2020-11-17       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.